SILVERARC CAPITAL MANAGEMENT, LLC Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001816307

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallHealth TiltHigh Turnover how tags are computed

Q3 2025 · 77 positions · Total reported value $705.63M · Top-10 concentration 45.7% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 64.6% · 15 new · 20 cut · 18 exited

Active Share (vs S&P 500): 99.8% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -8.8% · vs SPY -10.9% · Prev Value $855.33M — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -4.7% · vs SPY -6.9% · Latest Value $784.53M — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q3 2025 13F filing, SILVERARC CAPITAL MANAGEMENT, LLC disclosed 77 equity positions with a combined reported value of $705.63M. The filing implies a moderately concentrated portfolio: its ten largest positions account for 45.7% of reported value. HoldingsHub classifies the profile as Small / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2025 were ABVX ($45.82M), RYTM ($37.37M), RNAM ($36.80M). By sector, the heaviest allocations are Health Care 79.1%, Industrials 0.5%. Versus the prior quarter, allocation shifted toward Health Care (+23.0pp) and away from Consumer Discretionary (-0.7pp), Other (-22.7pp).

Versus the prior quarter, SILVERARC CAPITAL MANAGEMENT, LLC opened 15 new positions, trimmed 20 and fully exited 18, a turnover rate of 64.6% of positions. The portfolio's overlap with the prior quarter was 50% of names.

The largest new positions opened in Q3 2025 were ABVX ($45.82M), UTHR ($25.11M), CYTK ($11.60M).

Of the 18 positions fully exited versus the prior quarter, the largest were MRUS ($39.03M), VRNA ($33.89M), NBIX ($20.48M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2025)

  • ABVX ABIVAX SA · $45.82M
  • UTHR UNITED THERAPEUTICS CORP DEL · $25.11M
  • CYTK CYTOKINETICS INC · $11.60M
  • BIIB BIOGEN INC · $11.27M
  • AMLX AMYLYX PHARMACEUTICALS INC · $9.51M
  • VSTM VERASTEM INC · $9.21M
  • AVTX AVALO THERAPEUTICS INC · $9.16M
  • OLMA OLEMA PHARMACEUTICALS INC · $9.14M

Fully Exited (vs previous quarter)

  • MRUS MERUS N V · prev qtr: $39.03M
  • VRNA VERONA PHARMA ADR PLC ADR · prev qtr: $33.89M
  • NBIX NEUROCRINE BIOSCIENCES INC · prev qtr: $20.48M
  • ETNB 89BIO INC · prev qtr: $20.00M
  • SLNO SOLENO THERAPEUTICS INC · prev qtr: $17.14M
  • PFE PFIZER INC · prev qtr: $8.35M
  • HLXB HELIX ACQUISITION CORP II · prev qtr: $6.51M
  • MTSR METSERA INC · prev qtr: $5.91M

Insider Transactions (Form 4)

Latest SILVERARC CAPITAL MANAGEMENT, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Silverarc Capital Management is an SEC-registered 13F filer based in Boston, MA, United States. As of Q2 2026 it reported 67 US equity positions with a combined value of $855.33M. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: BOSTON, MA, United States
  • SEC registration: 801-116845 (status: Approved), registered 2019-06-21
  • Regulatory AUM (Form ADV): $1.61B as of 2026-03-30
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 3 private funds, of which 2 hedge funds
  • Website: silverarccapital.com

Portfolio Structure

  • 67 positions · $855.33M reported value (Q2 2026)
  • Top 10 holdings = 47.1% of reported value
  • Largest position: ASND (ASCENDIS PHARMA A/S) at 6.4%
  • Average position size: $12.77M

Sector Tilt

  • Health Care 98.1%
  • Financials 1.9%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 19 new, 16 added, 28 reduced, 20 exited
  • 4 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 79.1%
Other 20.4%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 539.70K $45.82M 6.49%
6.49%
New
2 370.00K $37.37M 5.29%
5.29%
Reduce
3 844.63K $36.80M 5.21%
5.21%
Add
4 372.30K $32.20M 4.56%
4.56%
Add
5 1.58M $31.47M 4.46%
4.46%
Reduce
6 643.64K $30.56M 4.33%
4.33%
Reduce
7 206.65K $29.76M 4.22%
4.22%
Reduce
8 674.97K $26.56M 3.76%
3.76%
Add
9 455.00K $26.56M 3.76%
3.76%
Add
10 638.35K $25.71M 3.64%
3.64%
Add
11 59.90K $25.11M 3.56%
3.56%
New
12 1.95M $23.39M 3.31%
3.31%
Add
13 220.90K $21.15M 3.00%
3.00%
Add
14 10.60M $16.85M 2.39%
2.39%
Add
15 1.36M $16.61M 2.35%
2.35%
Reduce
16 1.00M $16.37M 2.32%
2.32%
Add
17 4.78M $12.57M 1.78%
1.78%
Reduce
18 211.00K $11.60M 1.64%
1.64%
New
19 314.34K $11.32M 1.60%
1.60%
Add
20 80.42K $11.27M 1.60%
1.60%
New
21 53.55K $10.65M 1.51%
1.51%
Reduce
22 2.83M $9.92M 1.41%
1.41%
Add
23 700.00K $9.51M 1.35%
1.35%
New
24 1.04M $9.21M 1.30%
1.30%
New
25 720.92K $9.16M 1.30%
1.30%
New
26 933.54K $9.14M 1.29%
1.29%
New
27 348.92K $9.03M 1.28%
1.28%
Add
28 233.92K $8.71M 1.24%
1.24%
Reduce
29 235.79K $8.09M 1.15%
1.15%
Reduce
30 203.95K $6.06M 0.86%
0.86%
New
31 259.51K $5.60M 0.79%
0.79%
New
32 180.51K $5.42M 0.77%
0.77%
New
33 588.79K $5.39M 0.76%
0.76%
Add
34 457.41K $5.30M 0.75%
0.75%
New
35 994.75K $5.25M 0.74%
0.74%
Add
36 778.61K $5.17M 0.73%
0.73%
New
37 360.00K $5.17M 0.73%
0.73%
New
38 694.94K $5.15M 0.73%
0.73%
New
39 3.31M $4.87M 0.69%
0.69%
Add
40 183.90K $4.59M 0.65%
0.65%
New
41 88.69K $4.38M 0.62%
0.62%
New
42 2.72M $4.32M 0.61%
0.61%
Add
43 1.90M $4.21M 0.60%
0.60%
New
44 2.78M $4.15M 0.59%
0.59%
Hold
45 306.91K $4.08M 0.58%
0.58%
Add
46 250.61K $3.96M 0.56%
0.56%
New
47 276.27K $3.88M 0.55%
0.55%
Add
48 88.91K $3.45M 0.49%
0.49%
Add
49 141.24K $3.43M 0.48%
0.48%
Add
50 230.84K $3.29M 0.47%
0.47%
New

FAQ

What did SILVERARC CAPITAL MANAGEMENT, LLC buy in 2025-Q3?

In its 2025-Q3 13F filing, SILVERARC CAPITAL MANAGEMENT, LLC reported 77 equity positions worth $705.63M in aggregate; its largest disclosed positions were ABVX ($45.82M), RYTM ($37.37M), RNAM ($36.80M).

How large is SILVERARC CAPITAL MANAGEMENT, LLC's portfolio?

SILVERARC CAPITAL MANAGEMENT, LLC reported $705.63M of long equity holdings across 77 positions as of 2025-Q3. Top-10 holdings account for 45.7% of reported value.

What is SILVERARC CAPITAL MANAGEMENT, LLC's investment style?

HoldingsHub classifies the portfolio as Small / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/silverarc-capital-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →